Marketdash
Back to News

Nutex Health Shares Jump 21% After Massive Revenue Growth and Buyback Announcement

MarketDash Editorial Team
19 days ago
Nutex Health saw its stock surge nearly 21% in after-hours trading Tuesday after reporting explosive revenue growth and unveiling a $25 million share repurchase program. The healthcare company's second-quarter revenue more than tripled year-over-year.

Sometimes a healthcare stock does exactly what it's supposed to do when earnings come out. Nutex Health Inc. (NUTX) shares rocketed nearly 21% higher in after-hours trading Tuesday, hitting $120 after the company dropped some genuinely impressive numbers.

The stock had closed regular trading down 4.57% at $99.20, so the after-hours move was quite the reversal.

Revenue Growth That Actually Stands Out

The physician-led healthcare company reported second-quarter and year-to-date results that explain the enthusiasm. For the six months ended June 30, revenue reached $455.8 million compared to $143.5 million in the same period last year. That's a 218% jump. Second-quarter revenue alone came in at $244 million versus $76.1 million a year earlier, representing 221% growth.

Those aren't typo percentages. The revenue really did more than triple.

The Profitability Picture

Here's where things get interesting beyond the headline revenue numbers. For the first half of 2025, Nutex Health reported adjusted EBITDA of $144.4 million, up from $6.4 million in the prior year period. Operating income jumped to $114.3 million, an increase of $107.6 million year-over-year.

The company posted net income of $3.5 million and generated $78.2 million in net cash from operating activities during the first six months of 2025. As of June 30, Nutex had $96.7 million in cash and cash equivalents sitting on the balance sheet, with total assets of $841 million.

Buyback Program Signals Confidence

On August 14, the board authorized a $25 million stock repurchase program. The stated goals are straightforward: increase shareholder value and offset dilution from stock-based compensation.

CEO Tom Vo made the subtext text, stating, "The Company believes its shares are currently undervalued." Chief financial officer Jon Bates emphasized the company's "record high cash balance of $96.7 million" when discussing the buyback.

When management puts real money behind claims that shares are cheap, investors tend to pay attention.

The Broader Context

Nutex Health operates a healthcare delivery system spanning 24 micro-hospitals across 11 states. The Texas-based company has seen its stock surge 253% over the past year and 186% year-to-date, though shares are down 44% over the last six months.

The stock has traded in a wide range between $27.29 and $184.28 over the past year. With the after-hours jump, the company's market capitalization stands at roughly $551 million.

The combination of explosive revenue growth, improving profitability, strong cash generation, and a buyback program makes for a compelling narrative. Whether the after-hours enthusiasm holds up when regular trading resumes is the next question, but for now, Nutex shareholders have plenty to feel good about.

Back to News

Nutex Health Shares Jump 21% After Massive Revenue Growth and Buyback Announcement

MarketDash Editorial Team
19 days ago
Nutex Health saw its stock surge nearly 21% in after-hours trading Tuesday after reporting explosive revenue growth and unveiling a $25 million share repurchase program. The healthcare company's second-quarter revenue more than tripled year-over-year.

Sometimes a healthcare stock does exactly what it's supposed to do when earnings come out. Nutex Health Inc. (NUTX) shares rocketed nearly 21% higher in after-hours trading Tuesday, hitting $120 after the company dropped some genuinely impressive numbers.

The stock had closed regular trading down 4.57% at $99.20, so the after-hours move was quite the reversal.

Revenue Growth That Actually Stands Out

The physician-led healthcare company reported second-quarter and year-to-date results that explain the enthusiasm. For the six months ended June 30, revenue reached $455.8 million compared to $143.5 million in the same period last year. That's a 218% jump. Second-quarter revenue alone came in at $244 million versus $76.1 million a year earlier, representing 221% growth.

Those aren't typo percentages. The revenue really did more than triple.

The Profitability Picture

Here's where things get interesting beyond the headline revenue numbers. For the first half of 2025, Nutex Health reported adjusted EBITDA of $144.4 million, up from $6.4 million in the prior year period. Operating income jumped to $114.3 million, an increase of $107.6 million year-over-year.

The company posted net income of $3.5 million and generated $78.2 million in net cash from operating activities during the first six months of 2025. As of June 30, Nutex had $96.7 million in cash and cash equivalents sitting on the balance sheet, with total assets of $841 million.

Buyback Program Signals Confidence

On August 14, the board authorized a $25 million stock repurchase program. The stated goals are straightforward: increase shareholder value and offset dilution from stock-based compensation.

CEO Tom Vo made the subtext text, stating, "The Company believes its shares are currently undervalued." Chief financial officer Jon Bates emphasized the company's "record high cash balance of $96.7 million" when discussing the buyback.

When management puts real money behind claims that shares are cheap, investors tend to pay attention.

The Broader Context

Nutex Health operates a healthcare delivery system spanning 24 micro-hospitals across 11 states. The Texas-based company has seen its stock surge 253% over the past year and 186% year-to-date, though shares are down 44% over the last six months.

The stock has traded in a wide range between $27.29 and $184.28 over the past year. With the after-hours jump, the company's market capitalization stands at roughly $551 million.

The combination of explosive revenue growth, improving profitability, strong cash generation, and a buyback program makes for a compelling narrative. Whether the after-hours enthusiasm holds up when regular trading resumes is the next question, but for now, Nutex shareholders have plenty to feel good about.